Similarly, early clinical results from phase 1 trials with two different site-1 anti-IL-7Rα mAbs in healthy volunteers (GSK2618960, NCT02293161) or in type 1 diabetic adult patients (PF-06342674, NCT02038764) did not report induction of lymphopenia (https://www.gsk-clinicalstudyregister.com/files2/gsk-200902-clinical-study-result-summary.pdf)60. This evidence concerns the gene IL7R and lymphopenia.